Trump rips into Pfizer over COVID booster shots: ‘I saw the dollar signs in their eyes’

Former President Trump lashed out at COVID vaccine maker Pfizer over booster shots on Fox Business Wednesday and the potentially obscene profiteering they will engage in, stating, “I saw the dollar signs in their eyes.”

“You know what? That sounds to me like a money-making operation for Pfizer,” Trump said. “Think of the money involved. An extra shot — that’s tens of billions of dollars. How good a business is that? … The whole thing is just crazy.”

“Doesn’t — you wouldn’t think you would need a booster, you know when it first came out they were good for life. Then they were good for a year or two. I could see the writing on the wall. I saw the dollar signs in their eyes. The guy that runs Pfizer that announced the day after the election that he had the vaccine, we knew that… I knew that, and people knew that,” the former president contended.

Trump’s statement was in answer to host Maria Bartiromo on Fox Business asking him about the FDA recommending booster shots and then asking him if he would get one. He did not answer that question but ended with the accusation that Pfizer and their CEO Albert Bourla were looking to make more money from the pandemic and vaccines.

(Video Credit: Fox Business)

Pfizer Inc., BioNTech, and Moderna Inc. are all expected to reap billions of dollars from COVID-19 booster shots. The market for their vaccines and booster shots could rival the $6 billion in annual sales for flu vaccines according to analysts and healthcare investors.

A number of months ago, the companies started floating the idea that those who have been vaccinated will need a booster shot to maintain protection over time and to combat variant strains of the coronavirus and breakthrough infections.

Chile, Germany, and Israel are all lining up for the booster shots and the money just keeps rolling for Pfizer and the other COVID vaccine manufacturers.

The booster shots are being recommended to older individuals and those with compromised immune systems due to the Delta variant. With a worldwide aging population, the enterprise is a cash cow for vaccine makers.

On Thursday, the U.S. Food and Drug Administration authorized booster shots from Pfizer Inc. (PFE.N) and Moderna Inc. (MRNA.O) for those with compromised immune systems.

Pfizer and their German partner BioNTech, along with Moderna, have already locked up over $60 billion in sales for COVID vaccinations in 2021 and 2022. Established contracts include the supply of the initial two doses of their vaccines as well as billions of dollars in booster shots for wealthy nations.

Market analysts have forecasted revenue of over $6.6 billion for the Pfizer/BioNTech vaccine and $7.6 billion for Moderna as well in 2023. Most of that revenue will come from booster sales. The annual market is expected to settle out at around $5 billion or higher.

The World Health Organization has requested that governments hold off on booster shots until more people worldwide receive their initial inoculations. It’s not known exactly how effective booster shots will be or if they are even really needed after being fully vaccinated.

“We don’t know what the market forces will be,” Moderna President Stephen Hoge noted in an interview according to Reuters. “At some point, this will become a more traditional market – we’ll look at what are the populations at risk, what value are we creating, and what are the number of products that serve that value. That will ultimately impact price.”

Pfizer is not commenting on the issue currently. During the company’s second-quarter earnings call, executives said they think a booster shot will be necessary 6 to 8 months after vaccination, and regularly afterward. This guarantees an unlimited market and profits for the vaccine and booster shot industry.

People don’t trust Big Pharma and they don’t trust their vaccines:

Comments

Latest Articles